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Abstract
The impact of apo E polymorphism on interindividual variation in plasma lipid, lipoprotein concentrations, and 
LDL subfraction profiles was studied in 201 well-defined patients (88 men and 103 women) with familial combined 
hyperlipidemia (FCH). When corrected for the concomitant influences of age, gender and obesity, the allelic variation 
in the apo E gene was shown to explain a statistically significant portion of the variability in lipid and 
(apo)lipoprotein concentrations. Carriers of the apo e2 allele exhibited a substantially higher plasma triglyceride 
concentration and a lower low density lipoprotein (LDL) cholesterol level, while subjects with the apo eA allele had 
significant higher total plasma cholesterol and LDL cholesterol levels. In line with this observation, our FCH 
population was characterized by an over-representation of the apo E4 allele as compared with a Dutch standard 
population (x 2 = 55.2, P < 0.0001). The contribution of apo E polymorphism to trait variability was different between 
sexes for plasma triglyceride, VLDL cholesterol, VLDL triglycerides, and high density lipoprotein (HDL) cholesterol 
levels. Apo E polymorphism had no impact on chemical composition of VLDL; for LDL particles the apo el allele 
was associated with a lower cholesterol to protein (C/P) ratio, whereas the opposite was true for the apo s4 allele. 
Despite the demonstrated impact of apo E polymorphism on plasma lipids and LDL chemical composition, in all 
phenotypic groups a dense LDL subfraction profile predominated. Thus, apo E polymorphism contributes to the lipid 
phenotypic expression in FCH, whereas further evidence was obtained that a dense LDL subfraction profile is an 
integral feature of FCH.
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1. Introduction of a common defect assumed by its inherited
Familial combined hyperlipidemia (FCH) is a 
common heritable lipid disorder, in which affected 
individuals show elevations of plasma cholesterol,
total triglycerides or both, with lipid
phenotypes occurring within affected first-degree 
relatives, together with a high prevalence of pre­
mature cardiovascular disease [1-3]. Originally, it 
was supposed that FCH  was caused by the vari­
able expression of a single autosomal dominant 
gene with primary action on plasma triglyceride 
levels and secondary on cholesterol levels [1]. 
Nowadays, FCH is considered to be more hetero­
geneous, with on the one hand hepatic VLDL 
overproduction [4,5], possibly amplified by addi­
tional defects as insulin resistance, and on the 
other hand a deficiency in the clearance of circu­
lating triglyceride-rich lipoproteins [6], To the lat­
ter molecular defects in the LpL gene may 
contribute [7].
Apolipoprotein (apo) E, consisting of 3 com­
mon isoforms E2, E3 and E4, is one of the major 
protein constituents of chylomicrons and VLDL 
remnants, and is involved in the subsequent 
catabolism of these particles by allowing specific 
binding to hepatic receptors. Population studies 
have shown that the apo E polymorphism could 
explain a significant part of the inter-individual 
variability in plasma cholesterol and LDL choles­
terol [8 -10]. In these studies, the apo ¿'2 allele was 
frequently associated with lower levels of total 
plasma cholesterol, LDL cholesterol and apo B, 
whereas for the apo ¿4 allele the opposite was 
observed, inherent to the different binding activi­
ties of apo E isoproteins to the hepatic receptor 
[11-13]. Similar effects on lipid and lipoprotein 
concentrations due to apo E polymorphism were 
documented in a homogeneous sample of pi 
with familial 
same LDL receptor mutation [14]. These effects
i the
to be of age, and
body mass index (BMI), similar to reported epi­
demiological observations [15,16]. Consequently, 
the effects of apo E polymorphism, age, gender 
and BMI may, at least in part, also explain the 
great interindividual variability in lipid pheno­
typic expression in FCH, despite the probability
nature.
Therefore, the objective of this study was to 
estimate the specific impact of apo E polymor­
phism on plasma lipids, lipoproteins and LDL 
subfraction profiles in well-defined FCH patients, 
taking concomitant influences o f age, gender and 
BMI into account.
2. Subjects and methods
2.1. Families
As a part of an ongoing study aiming at the 
identification of biochemical and genetical aspects 
underlying FCH, extended FCH kindreds were 
recruited by family studies of probands attending 
the out-patient clinic of the Academic Hospital of 
Nijmegen. These probands repeatedly exhibited a 
combined hyperlipidemia with both plasma 
cholesterol and triglyceride concentrations above
the 90th percentile for age and gender. Families 
were only included when they satisfied the follow­
ing criteria: the presence of a multiple type hyper­
lipidemia in first-degree relatives with elevated 
levels of total plasma cholesterol and/or triglyce­
rides using the age- and sex-related 90th percentile 
upper levels of the prospective cardiovascular 
Münster (PROCAM) study [17]. Thus, besides a 
proband presenting a combined 
the presence of at least one first-degree relative 
with hypertriglyceridemia or hypercholesterolemia 
was obligatory. Furthermore, at least one of the 
first-degree relatives should have cardiovascular 
disease before the age of 60 years.
Families were excluded when first-degree family
members had xanthomata. All i Li a Is
were Caucasian with an age of 12 years or older. 
Information on medical status (i.e., diabetes, renal
impairment and liver 
alcohol intake, smoking habits, and hormonal 
status in women was collected by questionnaire. 
The study protocol was approved by the ethical 
committee of our Institute. None of the probands 
was homozygous for the apo i:2 allele or had 
hyperlipidemia due to a secondary cause (i.e., 
diabetes mellitus, hypothyroidism and hepatic or
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renal impairment), which was excluded by stan­
dard laboratory tests. Hypolipidemic drugs were 
discontinued at least 4 weeks prior to drawing of 
the blood.
2.2. Plasma
position of each VLDL or LDL particle is 
expressed in percentage of dry mass of each con­
tributing component (i.e., free cholesterol, choles­
terol esters, triglycerides, phospholipids and 
proteins). Total plasma apo B concentrations 
were determined bv immunonenh el om etrv 1701.
Overnight fasted venous blood samples were 
drawn by vein puncture into K3EDTA containing 
vacutainer tubes. Non-local participants were vis­
ited at their homes, and blood was transported 
directly to the laboratory. On arrival at the labo­
ratory within 2 h, plasma was isolated for deter­
mination of the lipid and lipoprotein levels, and 
the LDL subfraction profile.
2.3. Plasma lipid and lipoprotein assays and apo 
E  phenotype determination
VLDL was isolated from whole plasma by ul­
tracentrifugation at density 1.006 g/ml for 16 h at 
36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, 
Kontron, Zürich), in a Beckman L7-55 ultracen­
trifuge (Beckman, Palo Alto, CA). High density 
lipoprotein (HDL) cholesterol was determined by 
the polyethylene glycol 6000 method [18]. LDL 
cholesterol was calculated by subtraction of 
VLDL cholesterol and HDL cholesterol from to­
tal plasma cholesterol. For determination of its 
chemical composition LDL was isolated by se­
quential ultracentrifugation of the VLDL infrana- 
tant for another 20 h. Total cholesterol and 
triglyceride concentrations were determined by
enzymatic, commercially available reagents
M FRG, cat. no. 237574
Miles
tively). To obtain the chemical composition data 
of VLDL and LDL additional unesterified choles­
terol and phospholipids were determined using 
commercially available reagents (Boehringer-
Mannheim, FRG, cat. no. 310328, 691844). The 
protein content of VLDL and LDL was deter­
mined using the Lowry method [19] with chloro­
form extraction to remove turbidity due to lipids. 
From these data the mean ratio of cholesterol
To achieve accurate results in relation to the 
Center for Disease Control Standardisation Pro­
gram, the obtained values were recalculated on 
the basis of an exchange of sera with Dr. S 
Marco vina (Northwest Lipid Research Labora­
tory, Seattle, WA). Apo E phenotypes were deter­
mined after iso-electric focusing of VLDL 
lipoproteins, as described previously [21]. Results 
obtained for 534 samples agreed, with two excep­
tions, well in comparison to apo E genotyping 
according to Hixson et al. [22] (performed by Dr. 
M.J.V. Hoffer, MGC-Department of Human Ge­
netics, Leiden University, Leiden).
2.4. LDL sub fractionation
LDL subfractions were detected by single spin 
density gradient ultracentrifugation [23]. After ul­
tracentrifugation up to five LDL subfractions 
could be distinguished as distinct bands in the 
middle of the tube concentrated in the following 
density ranges: LDL1 (1.030-1.033g/ml), LDL2 
(1.033-1.040 g/ml), LDL3 (1.040-1.045 g/ml), 
LDL4 (1.045-1.049 g/ml), and LDL5 (1.049-
1.054 g/ml). The ultracentrifugation tubes, con­
taining the LDL subfractions stained with 
Coomassie Brilliant Blue R, were placed in a 
specially designed rack and photographed. Accu­
rate documentation of the different LDL subfrac­
tion patterns was obtained by scanning the 
obtained slides in triplicate on a LKB 2202 ultra­
scan laser densitometer (Pharmacia, Uppsala, 
Sweden). The mean peak heights (hl-h.5) of the 
LDL subfractions (LDL1-LDL5) on the three 
scans were used to calculate the variable K  as a 
continuous variable, that best describes each indi­
vidual LDL subfraction pattern [24]. The contri­
bution of each LDL subfraction, expressed by its 
peak height (%hl-%h5) relative to the total LDL
(unesterified cholesterol plus cholesterol moiety of subfraction profile, (total LDL [100%] — %hl +
cholesterol ester [ »  0.59*weight of cholesterol es- %h2 +  %h3 +  %h4 +  %h5), was calculated. The
ter]) to protein was calculated. The chemical com- relative peak heights of LDL3 and the less fre-
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quently occurring LDL4 and/or LDL5 were 
added to give %h3' =  (%h3 + %h4 +  %h5), where 
LDL[100%] = LDLl[%hl] +  LDL2[%h2] +  LDL3 
[%h3']. When a subfraction profile was charac­
terized by a predominance of buoyant LDL par­
ticles (h l-h 3 > 0 ), variable K was calculated by 
K =  (%h 1 -%h3r)/(%h2-%h3' +  1). In case of a 
predominance of heavy, dense LDL subfractions 
(h l-h 3 < 0 ), variable K  was calculated by: K = 
(%hl-%h3')/(%h2-%hl +  1). A negative value
( 1 < K  < 0) reflects a dense LDL subfraction
profile and a positive K  value (0 < K  < 1 ) a 
buoyant profile.
2.5. Statistical methods
All statistical analyses were performed for af­
fected FCH relatives as a group and because of 
different frequency distributions in men and 
women for plasma lipids, lipoproteins, and con­
comitant effects (i.e. age and BMI), shown by 
epidemiological studies [15,25], also an addi­
tional analysis was performed for men and 
women separately. Differences between men and 
women for the quantitative trait means depicted 
in Table 1 were evaluated by Student’s t test.
Allele frequencies were determined by the gene- 
counting method under the hypothesis of a 
Hardy-Weinberg equilibrium. Differences in apo 
E phenotype frequencies between FCH relatives 
and either spouses or a representative sample of 
the Dutch population [8] were evaluated by the 
X 2 test. Multiple regression analysis was used on 
the parameters to estimate the possible concomi­
tant effects of age, gender, BMI, smoking habits, 
and hormonal status in women. Initially, af­
fected FCH subjects were distinguished from un­
affected relatives on the basis of elevated lipid 
concentrations (total plasma cholesterol ^6.5  
mmol/1 and/or plasma triglycerides S:2.0 mmol/ 
1). By this classification age, gender and BMI 
significantly contributed to the variation of a 
majority of the parameters, whereas smoking 
habits and hormonal status in women did not. 
When percentile data (total plasma cholesterol 
and/or total plasma triglycerides > 90th percen­
tile for age and gender) were used to identify 
affected relatives, age and BMI did not con­
tribute anymore to the variation in the parame­
ters, since these concomitant effects appeared to 
be incorporated in the percentile data itself. 
Therefore, the actually presented analyses were 
performed with data of relatives classified by us­
ing the percentile data. A two-way ANOVA 
with independent variables ‘apo E phenotype’ 
and ‘sex’ towards dependent lipid parameters 
followed by Scheffe’s post-hoc multiple compari­
son test was performed to determine the effects 
of apo E polymorphism on plasma lipids, 
(apo)lipoproteins, the chemical composition of 
VLDL and LDL and the LDL subfraction 
profile, for each sex separately. Statistical analy­
ses were performed by the Department of Medi­
cal Statistics using procedures available in the 
Statistical Analysis System software package 
(SAS Institute, Cary, N.C.). A trait difference 
with P < 0.05 was considered to be significant.
Table 1
Description o f independent and dependent measures in the 
affected FCH subjects
Women (n 
1 13 )
Men (n = 88) P value
• ‘ “ ■‘ • ' i n  M É liT tM
Independent
Age (years) 47.3 ±16 .8 45.1 ±15.5 N.S.
BMI (kg/m2) 26.3 ±  3.9 26.7 ±  3.2 N.S.
Dependent 
Total choles­ 6.91 ±  1.35 7.12 ±  1.25 N.S.
terol1
Triglycerides" 2.75 ± 1 .75 4.03 ±3.16 0.001
VLDL- 1.19 ± 0 .93 1.85 ±  1.44 <0.001
cholesterol"
VLDL- 1.86 ±  1.46 3.04 ±  2.70 <0.001
triglycerides“
HDL-choles- 1.14 ± 0 .34 0.90 + 0.26
m m *
<0.001
terol“
LDL-choles- 4.58 ±  1.26 4.39 ±  1.33 N.S.
terol“
Apolipoprote 168.8 ± 3 5 .3 181.1 ±38.7 0.04
iii-B (mg/dl) 
K value -0 .4 1  ± 0 .27 -0 .5 1  +0.24 0.001
-  m r t f i -  r v f
Values are presented as mean ±  S.D.; N.S., not significant, 
" in mmol/1.
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Table 2
aThe apo E phenotype and allele frequencies in 2018 randomly selected 35-year-old Dutch males (8). 
bRepresents the apo E phenotype and allele frequencies in the spouses o f FCH relatives.
Differences between different population samples were analyzed by x2 analysis; N.S., not significant.
Apo E phenotype and allele frequencies
populations
in our FCH population (affected and unaffected subjects), compared to two contr
Apo E pheno­ Standard Dutch con- All FCH relatives Affected (n — Unaffected relatives Spousesb (n —
types trol population“ (n = (n =  558) 201) (n = 357) 102)
2018)
n (%) n (%) n (%) n (%) n (%)
E2/2 13 (0.01) 7 (0.01) 0 (0.00) 6 (0.02) 1 (0.01)
E3/2 261 (0.13) 66 (0.12) 27 (0.13) 39 (0.11) 13 ((). 13)
E3/3 1128 (0.56) 257 (0.46) 75 (0.37) 180 (0.50) 57 (0.56)
E4/2 45 (0.02) 22 (0.04) 10 (0.05) 13 (0.04) 4 (0.04)
E4/3 512 (0.25) 165 (0.30) 67 (0.33) 100 (0.28) 24 (0.23)
E4/4 59 (0.03) 41 (0.07) 22 (0.11) 19 (0.05) 3 (0.03)
Alleles
i:2 332 (0.08) 102 (0.09) 37 (0.09) 64 (0.09) 19 (0.09)
« 3 3029 (0.75) 745 (0.67) 244 (0.61) 499 (0.70) 109 (0.74)
t;4 675 (0.17) 269 (0.24) 121 (0.30) 151 (0.21) 27 (0.17)
X2 — 35.1 X2 -  47.1 X z =  9.4 £ 2 =  0.31
df =  2 df =  2 df =  2 df — 2
P <  0.0001 P<  0.0001 P =  0.009 N.S.
3. Results
3.1. Subjects
In total, 40 multi-generational FCH kindreds 
including 660 individuals (558 FCH relatives and 
102 spouses) were used in this study. Based on 
percentile data, 201 individuals were found to be 
affected by exhibiting a total plasma cholesterol 
and/or a plasma triglyceride concentration above 
the 90th percentile for age and gender. The an­
thropometric measurements of the affected sub­
jects, as well as the plasma lipid and lipoprotein 
levels (88 men and 113 women) are shown in 
Table 1. Both in men as well as in women mean 
age and BMI were similar. Men exhibited higher 
concentrations of plasma triglycerides, VLDL 
cholesterol, VLDL triglycerides and apo B, and 
lower concentrations of HDL cholesterol. Total 
plasma cholesterol and LDL cholesterol concen­
trations were not different between sexes. Despite 
lower triglyceride levels in women, both sexes 
had, on the average, a substantial negative K  
value, which represents a LDL subfraction profile
in which small dense LDL particles predominate. 
This feature was more pronounced in men.
3.2. Phenotype and allele frequencies
Table 2 depicts the phenotype and allele fre­
quencies in our sample of Dutch FCH patients 
and unaffected relatives compared to a standard 
Dutch control population [8]. Apo E phenotype
and apo i: allele frequencies in spouses (n 102)
were similar compared to the Dutch control pop­
ulation, but differed significantly from those in
and unaffected FCH relatives (Table 2).
frequency was comparable in 
and controls, but the apo rA
relatives, especially in
The apo e.2 
both FCH rek
frequency in 
FCH patients, was higher.
3.3, Effects o f  apo E
o teins
on
The impact of apo E polymorphism on trait 
means in the 88 male and 113 female 
FCH relatives is summarized in Table 3. Reported
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Plasma concentrations of lipids, lipoproteins and apolipoproteins according to apo E phenotypes in 201 affected subjects of a FCH
Tabic 3
T nut 
Number
Sex
9
3
Apo E phenotypes
E3/2
15
12
E3/3
40
35
E4/2
6
4
E4/3
41
26
E4/4
11
11
P value1
TC n1 5.88 ±  1.27 7.10 ±  1.38 6.51 ±0.81 6.99 ±  1.36 7.51 ± 0 .84 0.025
7.15 ±2 .13 7.32 ±  0.89 6.00 ±  0.82 6.77 ±  0.92 7.30 ±  1.34
TG 9 3.49 ± 2 .34 2.88 ±  2.05 2.89 ±  2.08 2.59 ±  1.13 1.84 ±  0.93c 0.009
Ö 6.13 ±4.29 3.49 ±3.25 4.08 ±  2.50 4.05 ±  2.97 2 .7 0 +  1.74c
V L D L-C 9 1.25 + 0.82 1.30 ±  1.09 1.43 ±  1.18 1.14 ±0.83 0.76 ±  0.58 N.S,
<îb 2.84 ±  2.20 1.55 ±  1.34 1.83 ±1.12 1.75 ±  1.19 1.42 ±  0.93
VLDL-TG ? 2.37 ± 1.97 2.03 ±  1.97 2.13 ±  1.77 1.66 ±0.95 1. 15 ±  0.84e 0.009
<îb 4.97 ±3.83 2.58 ±  2.84 3.10 ±  1.97 3.04 ±  2.37 1.92 ±  1.2 Ie
FID L-C V 1.15 + 0.40 1.14 ±  0.40 1.04 ±0.38 1.11 ±0.25 1.27 ±0.30 N.S.
s b 0.91 ±0.38 0.96 ±  0.22 0.86 ±0.19 0.89 ±  0.21 0.85 ±0 .36
L D L-C 01 3.49 ±  1.08dd» 4.66 ±  1.12 4.01 ±  1.47' 4.74 ±  1.25° 5.49 ±  1,04cc <0.001
3 3.40 ±  1.24dd 4.79 ±  1.22 3.31 ± 0 .4 5 r 4.14 ±  1,09e 5.10 ±  1.56“
LDL-TG 9 0.50 ±0 .16 0.44 ± 0 .12 0.36 ±0 .19 0.48 ± 0 .1 4 0.43 ± 0 .12 N.S.
3 0.52 ±0.21 0.46 ± 0 .17 0.35 ±0.11 0.44 ± 0 .12 0.59 ±  0.25
Apo-B 9 161.2 ± 55 .4 169.7 ±31 ,9 151.6 ±31.8 174.1 ±33 .7 168.0 ±  19.6 N.S.
.
3 187.0 +  41.0 176.7 +  35.6 168.2 +  16.7 172.5 ±  33.4 193.4 +  33.6
Values are presented as mean ±  S.D. in mmol/1 for lipids and lipoproteins and in mg/1 for apoprotein-B; TC total plasma cholesterol; 
TG total plasma triglycerides.
il Differences between 5 phenotypes if both men and women are considered together; h sex difference P <  0 .01.Scheffe’s post hoc tests: 
0 ƒ><0.05; «  P < 0.001 E3/2 vs. E4/4; **ƒ>< 0.001 E3/2 vs. E3/3; c P<0.05 E3/2 vs. E4/3; '7 '<0 .05  E3/2 vs. E4/3.
N.S. not significant.
alcohol intake and smoking habits ap­
peared to be similar among the apo E phenotype 
groups. Of all 558 FCH relatives 6 individuals 
had an apo E2/2 phenotype without exhibiting a 
hyperlipidemia. With the whole group of affected
ences related to gender were ob- 
for plasma triglycerides, VLDL choles-ser
tcrol, VLDL triglycerides and HDL cholesterol. 
The significance of the overall difference for the 
traits between the 5 apo E phenotypes is depicted 
by the P value in Table 3. When phenotype means 
were compared mutually for both sexes, signifi­
cant differences between the phenotypes could be 
observed for plasma triglycerides (phenotype E3/2 
versus E4/4, Scheffe’s test P < 0.05), VLDL 
triglycerides (phenotype E3/2 versus E4/4, 
Scheffe’s test P < 0.05) and LDL cholesterol (phe-
notype E3/2 versus E3/3 and E4/4 
P < 0.001, and versus E4/3 and E4/2 Sc 
P < 0.05). Within
apo E
concentration
total plasma
3.4. Effects o f  apo E  polymorphism on VLDL  
and LD L
Apo E polymorphism had no delectable effect
on VLDL chemical
shown), m en
(data not 
an overall
lower protein content, and therefore a higher C/P 
ratio in all phenotype groups (data not shown), in 
agreement with the slightly lower K  values in the 
males. On the contrary, apo E polymorphism had
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Chemical composition of low density lipoproteins (in % dry mass) according to apo E phenotypes in 201 affected subjects with FCH
Table 4
Trait Sex Apo E phenotypes
E3/2 E3/3 E4/2 E4/3 E4/4 P value1'
%FC S ' 7.8 +  1.4 7 .9 +  1.5 8.8 +  1.9 7.9 ±  0.9 8.6 ±  0.8 N.S.
*
* 7.0 ±  1.8 7.6 ±  1.2 6.6 + 0.5
■ l ^ l l  m*
7.3 ± 1.0 8.0 ± 1 .6
%CE V 35.6 ±  5.6 37.2 ± 8 .6 41.7 + 6.3 40.2 +  3.9'1( t u r n 43.4 + 4.0CC 0 . 0 0 1
o 33.7 ±  8.0 40.3 + 4.5 38.8 ±3.1w u w f t 39.9 ±  4.6‘‘ 41.3 +  7.9«
%TG V 10.4 +  3.5CC 8 .1 +  3.0 7.4 + 2.6 8.3 + 2.4lUI 7.3 ±  2.8 0.002
r tO 14.2 + 7.9CC 8.5 ±  5.5 8.3 ±  3.2 8.5 + 3.4,kl■ M M « 9.8 ±  5.5
%PL V 20.8 + 1.4 20.4 ± 3 .3 16.0 + 7.2 18.3 ± 5 .2 17.1 ±  6.41 0.002
< s 18.4 + 6.6N i l  I I I 20.1 ± 2 .0 18.6 ± 0 .7 17.7 ± 4 .8 14.2 +  8.4r
%PROT < "  ) 1 25.4 +  3.3 26.5 ±  7.0 26.2 ±  4.6 25.3 ±  2.4 23.8 ±  2.2 N.S.
26.7 ± 2 .7 23.5 ± 2 .4 27.8 ± 0 .2 26.6 ±  2.4 26.7 ± 3 .3
C/P ratio V 1.17 ±  0.26e 1.22 ±0.31 1.32 ± 0 .30 1.27 ±0 .16 1.45 ±  0.15* 0.009
1.04 ±  0.29c 1.37 ± 0 .27 1.07 ±  0.08 1.18 ±  0.20 1.23 ±0.23*
Values are presented as mean ±  S.D.; FC free cholesterol; CE cholesterol ester; TG triglycerides; PL phospholipids; PROT proteins; 
C/P ratio, the ratio o f cholesterol (i.e. FC +cholesterol moiety of CE [ t* 0.59*weight of CE]) to protein; ADifferences between 5 
phenotypes if both men and women are considered together; b sex difference P<0.05.
Scheffe’s post hoc tests: e P < 0.05; “  P < 0.01 E3/2 vs. E3/3; “ P<0.05; dd P<0.01 E3/2 vs. E4/3; 6 P < 0 .0 5 ;“  P<0.01 E3/2 vs. E4/4; 
f\P<0.01 E3/3 vs. E4/4.
N.S. not significant.
a significant effect on chemical composition data 
of LDL particles (Table 4). The relative choles­
terol ester content was lower in subjects with 
phenotype E3/2 compared with those with E4/3 
(Scheffe’s test P < 0.05). The same was true when 
compared with subjects with E4/4 (Scheffe’s test 
P C  0.01). The triglyceride content was higher in 
individuals with phenotype E3/2 compared with 
those with E3/3 and E4/3 (Scheffe’s test P < 0.01).
The phospholipid content was significantly lower 
in subjects with phenotype E4/4 compared with 
those with E3/3 (Scheffe’s test P  <  0.01) (Table 4). 
A sex difference was observed for the free choles­
terol content and for the C/P ratio. This C/P ratio
in subjects with E3/2 compared with
test P <{).05) andV7* fsubjects with E3/3 
higher in subjects with E4/4 compared with
with E3/2 (Table 4).
3.5. Effects o f  apo E  polymorphism on L D L  
sub fra  c t ion distribution
The distribution of LDL subtractions in a LDL
•action profile were both described by the 
amount of cholesterol measured in each separated 
LDL subfraction (Fig. 1), and by the continuous 
variable K , taking the relative contribution of
LDL subfraction into account 5).
Data of 12 affected subjects were missing due to 
technical errors or lack of sufficient amount of
a. As a consequence of the effect of apo E 
rphism on total plasma LDL cholesterol, 
individual LDL subfraction cholesterol 
concentrations were observed in patients with the 
apo E4/4 lowest with apo E3/2 
phenotype (Fig. 1). However, no effect of apo E 
polymorphism on the distribution of LDL sub­
fractions pattern was observed, despite the estab-
quantitativc
(apo 
relatives a pre
and 
FCH
inance of heavy LDL 
ative K  values in all 
apo E phenotype groups (Table 5). Men showed 
more dense LDL subfraction profiles (i.e. more
K  values) than women. Additionally,
b y
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2.00 ' • *  r -  • '  - * —  * * v * - .  . 1  * v .  i
1.00‘
1.00 -
0 . 3 0
o.oo
LDL 1 LDL2 LDL 3
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Fig. 1. Cholesterol content of 5 isolated LDL subfractions contributing to the total LDL subfraction profile according to the 
apolipoprotein E phenotypes of 189 affected FCH patients. The black and the hatched bars represent men and women, respectively. 
Mean sex-difference if all apo E phenotypes are considered together for LDL I P =  0.006, for LDL2 P — 0.016, for LDL3 P — 0.026, 
for LDL4 n.s., and for LDL5 n.s.
*P <  0.05, **/><0.01 when equivalent LDL subfractions are compared with E4/4, # P <  0.05 E3/2 vs. E3/3 or E4/3, all 
differences are observed both for men and women.
each apo E phenotype showed a predominance of
tration in LDL1 (Fig. 1).
4. Discussion
Although the genetic nature of FCH seems
molipidemic subjects [8-10,12] and in liyperc- 
holesterolemic subjects [14], associated with the 
apo E phenotype. In the present study, we could 
demonstrate that the apo E polymorphism also 
contributes to the magnitude of lipid and lipo-
S.J.H. Bredìe et al. / Atherosclerosis 126 (1996) 313-324 321
Distribution of LDL subfraction profiles, described by a continuous variable K according to apo E phenotypes in 189 affected 
subjects of a sample of Dutch FCH families
Table 5
Trait Sex Apo E phenotypes
Number 
K -value
Values are presented as mean +  S.E.M.; JDifferences between 5 phenotypes if both men and women are considered together; b sex 
difference P =  0.004.
E3/2 E3/3 E4/2 E4/3 E4/4 .P-value3
9
$
9
15
12
0.34 + 0.06 
0.45 +  0.07
39
31
0.44 ±  0.05 
0.52 +  0.05
5
3
0.36 + 0.13 
0.67 +  0.07
40
23
0.46 + 0.04 
0.52 + 0.04
11
10
0.25 +  0.08 
0.45 +  0.12
N.S.
protein concentrations among affected subjects of 
40 well-defined FCH families.
Like familial dysbetalipoproteinemia (FD) in 
which other factors next to the apo E2/2 pheno­
type contribute to the expression of the hyperlipi- 
demia [26], a similar coincidence of factors may 
appear in FCH. Clearly, the presumed overpro­
duction of VLDL particles as a primary cause of 
FCH, would be exaggerated by the differential 
effect of the apo e2 allele on VLDL remnants and 
of the apo s4 allele on LDL cholesterol. The effect 
of the apo s2 allele was confirmed by the observed 
accumulation of beta-VLDL in FCH subjects 
with extensive premature atherosclerosis related 
to a heterozygote apo E3/2 pattern [27], which 
was independent of the LDL receptor status as 
reported by others [28], In our FCH sample, 
indeed, higher VLDL cholesterol and triglycerides 
concentrations were observed in subjects with apo 
E3/2. The observed elevated LDL levels in sub­
jects with the possession of an apo E4 allele 
hypothetically results from the more efficient up­
take of chylomicrons and VLDL remnants by the 
liver increasing intracellular cholesterol, thereby 
reducing LDL receptor activity and thus elevating 
plasma LDL cholesterol levels [11].
When apo E alleles effects are primarily related 
to FCH, the allele frequency would deviate from 
normal. In a comparative study between hyperc- 
holesterolemic patients and non-obese patients 
with combined hyperlipidemia (serum cholesterol 
> 7 .5  mmol/1 and serum triglyceride > 2.0 mmol/ 
1) the apo s2 allele, together with smoking habits
and fasting insulin concentrations explained 30% 
of the hypertriglyceridemia and the low HDL- 
cholesterol levels [29], Besides specific apo s2 re­
lated differences on plasma lipids, also the 
frequency of the apo s2 allele was higher in the 
combined hyperlipidemic group, which confirms 
that the apo s2 allele has a plasma triglyceride 
raising effect in primary hypercholesterolemic pa-
We
significant
presence of apo s4 in our sample of FCH patient 
as compared with a representative Dutch control 
population [8] and the spouses in this study. The 
apo s2 frequency similar to the representation in 
the control population is in agreement with the
confirming
normal
Consequently, this may imply that apo E2 iso­
form has only secondary modulating effects on 
the expression of FCH. The over-representation 
of apo E4 in our sample corresponds with results 
in strictly unrelated patients with primary com­
bined hyperlipidemia [31], and also with the fre­
quency found in patients with coronary heart 
disease [32,33]. Moreover, the normal apo E allele 
distribution in the spouses of our FCH families 
suggests that the over-representation of apo s4 is 
not simply explained by a high apo e4 allele 
frequency in spouses. Therefore, Hoiilston et al. 
suggested that the possession of the apo E4 allele 
is one of the predisposing genetic factors to the 
development of the combined hyperlipidemic phe­
notype of FCH [31].
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Although affected subjects with hypertriglyce­
ridemia and the apo E3/2 phenotype may exhibit 
a relative increase of triglyceride in VLDL parti­
cles, on average, VLDL particles were not af­
fected in their composition by qualitative 
differences in the apo E isoprotein content. Fur­
thermore, no increase of cholesterol content as 
seen in so called VLDL remnants could be ob­
served with the apo E 3/2 phenotype. This appar­
ent homogeneity of VLDL particles in FCH 
comparable with VLDL of normolipidemic sub­
jects has been reported several times [4,34,35]. 
Our results affirm that the produced VLDL parti­
cles maintain their normal composition irrespec­
tive of the apo E isoprotein component. So, the 
accumulating effects of apo E2 on VLDL parti­
cles may be subordinate to the overproduction. 
Furthermore, diminished catalytic LpL activity in 
FCH [6] may prevent increased VLDL remnant 
formation. The effects of apo E phenotypes on 
LDL particle composition reflect the effects as 
observed on plasma lipids. These compositional 
changes are potentially associated with alterations 
in LDL heterogeneity [36]. A high cholesterol 
ester content and high C/P ratio is usually associ­
ated with large buoyant LDL particles, whereas a 
high triglyceride content and low C/P ratio coin­
cides with small dense LDL particles [36,37]. Only 
in women with apo E4, exhibiting elevated LDL 
cholesterol and low plasma triglyceride concentra­
tions the buoyant LDL1 and LDL2 subfractions 
predominated. Surprisingly, no significant differ­
ences in the overall dense LDL subfraction profi­
les between the various apo E phenotype groups 
were observed. Thus, the affected FCH subjects in 
this sample could be distinguished by the presence 
of a small dense LDL subfraction profile, as 
reported previously [38-41], despite the docu­
mented variation in plasma lipids. We considered 
several explanations for this apparent contradic­
tion: (i) the compositional differences in LDL due 
to apo E polymorphism may be too small to 
cause identifiable changes in LDL subfraction 
profiles; (ii) it has to be noted that all LDL C/P 
ratios were below 1.45, which is usually associated 
with dense particles [36]; and (iii) pharmacological 
studies in FCH patients showed the persistence of 
small dense LDL particles in FCH patients de­
spite substantial reduction of plasma triglyceride 
concentrations by gemfibrozil administration 
[39,40]. This is in line with the identification of a 
major gene effect on the small dense LDL sub­
fraction distribution in these FCH families [41].
In conclusion, in the genetically and metaboli- 
cally heterogeneous lipid disorder FCH we 
demonstrated that the apo E polymorphism by 
itself contributes significantly to the lipid and 
lipoprotein concentrations of affected subjects, in­
dependent of its allele frequency. It is likely that 
in FCH populations the apo e4 allele is slightly 
over-represented. However, apart from this, apo 
E polymorphism itself has no distinct effect on the 
distribution of LDL subfractions. This finding 
provides further evidence that a LDL subfraction 
profile consisting of small dense LDL particles is 
a characteristic feature in FCH patients, irrespec­
tive of apo E related impact on plasma lipid and 
lipoprotein concentrations.
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